NHS to Roll Out ‘1-Minute’ Immunotherapy Jab to Tens of Thousands with Cancer

Key Takeaways

• Subcutaneous Keytruda injection reduces administration time by up to 90%.
• One‑minute jab treats 14 cancer types, replacing two‑hour IV infusions.
• NHS expects 14,000 annual patients to benefit from faster dosing.
• Faster injections free clinic space, boosting capacity for more cancer patients.
• Three‑week or six‑week schedule matches tumor type, improving treatment flexibility.

Pulse Analysis

Pembrolizumab, sold as Keytruda, has become a cornerstone of modern immunotherapy, enabling the immune system to target a broad range of tumors. The new sub‑cutaneous formulation delivers the drug under the skin in a ready‑to‑administer syringe, cutting administration time from up to two hours to a single minute. Patients with lung, breast, head‑and‑neck, cervical and ten other cancers will experience less disruption to daily life, while clinicians can maintain dosing schedules without the logistical burden of sterile IV bag preparation.

From an operational perspective, the shift to a one‑minute jab addresses two chronic NHS challenges: limited infusion chair capacity and time‑intensive pharmacy workflows. Preparing IV bags under sterile conditions consumes valuable staff hours, and each infusion occupies a treatment chair for up to two hours. By eliminating the preparation step and freeing up chairs, hospitals can accommodate more appointments, reduce waiting lists, and improve overall throughput. The expected impact on the 14,000 annual pembrolizumab users is a net gain in clinical efficiency and patient satisfaction, aligning with the government’s record funding commitments for cancer care.

The rollout also signals a broader industry trend toward sub‑cutaneous delivery of biologics, which promises cost savings, lower staffing requirements, and enhanced patient adherence. As other manufacturers follow suit, the NHS could see a cascade of similar innovations across oncology and chronic disease management. This transition may accelerate the adoption of home‑based or community‑clinic treatments, reshaping how cancer care is delivered in the UK and potentially setting a benchmark for health systems worldwide.